Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
COMBO Plus
- Development stage
- Unknown
- Lead developer
- OrbusNeich
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intra-arterial
01
Overview
The COMBO Plus is a second-generation dual therapy stent (DTS) designed for the treatment of coronary artery disease. It represents a unique drug-device combination that integrates pro-healing and anti-restenotic technologies. The stent features a circumferential coating of murine monoclonal anti-human CD34 antibodies, which are designed to capture circulating endothelial progenitor cells (EPCs) from the bloodstream to promote rapid endothelialization and vessel wall repair. Simultaneously, it utilizes an abluminal coating of sirolimus (an mTOR inhibitor) embedded in a biodegradable polymer to inhibit smooth muscle cell proliferation and prevent neointimal hyperplasia. This dual mechanism aims to provide the efficacy of a drug-eluting stent while potentially reducing the risk of late stent thrombosis and allowing for a shorter duration of dual antiplatelet therapy (DAPT).
- Brand names
- COMBO PlusCOMBO
- Other names
- COMBO Plus Dual Therapy StentCOMBO DTS
02
Targets
mTOR (Mammalian target of rapamycin kinase)
Beyond the preview
Go deeper on COMBO Plus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on COMBO Plus.